“…[7][8][9][10][11][12][13] However, most of these inhibitors either display significant affinity for the a 2 -adrenoceptor (e.g., 1,2), 10,14 which complicates the interpretation of their biological effects, or those inhibitors that are selective for PNMT are too polar to pass the blood-brain barrier (BBB) (e.g., 3,4). 8,12,15 In light of these limitations, there remains an ongoing interest in the development of a PNMT inhibitor that is both sufficiently lipophilic to penetrate the BBB and is devoid of affinity for the a 2 -adrenoceptor.…”